Physician profile
Asfa Akhtar
NPI 1245434588
$35,285.84
in general payments reported to CMS, 2019-2025
29 companies · $32K in 2025
The $32K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $147 · 2021: $254 · 2022: $646 · 2023: $89.44 · 2024: $1,626 · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Consulting Fee: $4,710 · Food and Beverage: $4,188 · Travel and Lodging: $271 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,600.00 |
| Consulting Fee | $4,709.54 |
| Food and Beverage | $4,188.32 |
| Travel and Lodging | $270.60 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $31,065.45 | 2019-2025 | Nemluvio, Aklief |
| Abbvie INC. | $725.22 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $555.25 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $470.79 | 2020-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $227.93 | 2019-2025 | |
| Incyte Corporation | $209.13 | 2021-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $200.58 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $197.34 | 2024-2025 | Zoryve |
| Amgen INC. | $195.23 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $173.07 | 2024-2025 | Bimzelx |
| Biofrontera INC. | $122.63 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Paratek Pharmaceuticals, INC. | $121.99 | 2024 | Nuzyra |
| Sun Pharmaceutical Industries INC. | $116.17 | 2024-2025 | |
| Celgene Corporation | $110.13 | 2019 | |
| Janssen Scientific Affairs, LLC | $110.07 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $90.21 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Convatec INC. | $76.42 | 2025 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $69.31 | 2025 | Dupixent, Libtayo |
| Pfizer INC. | $62.09 | 2024-2025 | |
| Pierre Fabre Pharmaceuticals, INC. | $61.16 | 2019 | |
| Almirall LLC | $45.61 | 2024-2025 | Seysara |
| Strata Skin Sciences, INC. | $45.06 | 2025 | Xtrac |
| Leo Pharma INC. | $43.92 | 2022-2025 | Adbry |
| Botanix Sb INC | $35.73 | 2025 | Sofdra |
| Organon LLC | $29.08 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.10 | 2024 | Cabtreo |
| Lnhc, INC | $18.30 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.87 | 2024 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asfa Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.